RxDoctor Payments Data

Kenesha Ricketts

Psychiatric/Mental Health · Miami Gardens, FLNPI 1285312157

Payments from drug & device makers

$392in general payments, 2019–2025

Across 14 payments — averaging $28.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$134
  • AbbVie$68
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$39
  • Livanova USA, Inc.$39
  • Corium, LLC$30
  • Alkermes, Inc.$23
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$392100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$392 in reported general payments places this provider in the 35th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$13,039
Medicare patients
46
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine20$111,241
SpravatoEsketamine Hcl70$94,032
VraylarCariprazine Hcl20$30,576
Lurasidone Hcl20$5,492
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$2,782
Aripiprazole49$2,570
Bupropion XlBupropion Hcl66$1,044
Duloxetine Hcl40$921
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine14$917
Clonazepam79$888
Buspirone Hcl66$688
Sertraline Hcl80$559
Oxcarbazepine16$523
Quetiapine Fumarate48$451
Venlafaxine Hcl17$426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$18$94,03270 claims
AbbVieVraylar$68$30,57620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Miami Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →